Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | DRD5 | P21918 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21421582 | 0.87 | HRH3 (0.49) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL19959005 | 0.83 | HRH3 (0.53) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL14349615 | 0.76 | KDM4E (0.52) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21933624 | 0.75 | HRH3 (0.51) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL21421763 | 0.75 | HRH3 (0.43) | HRH3DRD2DRD1DRD3DRD5 | |
| SCHEMBL2733014 | 0.74 | SMN1; SMN2 (0.50) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21419372 | 0.74 | HRH3 (0.53) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11932478 | 0.73 | DRD4 (0.53) | DRD2DRD1DRD3KDM4EALDH1A1 | |
| SCHEMBL21419341 | 0.73 | KMT2A (0.49) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27707250 | 0.73 | SMN1; SMN2 (0.56) | DRD2DRD1DRD3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | HRH3 2096/4885DRD2 2944/4885DRD1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.